Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Celmatix Partner on Women's Reproductive Health Drug Discovery

NEW YORK — Evotec and Celmatix said today that they have formed a drug-discovery partnership focused on prevalent but underserved women's reproductive health conditions including polycystic ovary syndrome, endometriosis, and infertility.

Under the terms of the alliance, Hamburg, Germany-based Evotec will be responsible for medicinal chemistry and in vitro and in vivo pharmacology activities. Celmatix — which recently launched a division to discover therapeutics for women's health indications including reproductive disorders — will contribute to drug-discovery efforts using its Reproductive Atlas platform, which combines biological annotations from peer-reviewed literature with genomic data associated with lifestyle, diet, environment, and reproductive outcomes.

Additional terms were not disclosed.

"Through combining our vast datasets and deep expertise in women's health with Evotec's proven experience in therapeutic discovery, we are poised to catalyse real change and finally provide women therapies they deserve," Piraye Yurttas Beim, founder and CEO of New York City-based Celmatix, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more